Dopamine: Pharmacologic and therapeutic aspects

American Journal of Therapeutics

Volumn 5, Issue 1, 1998, Pages 37-43

  Velasco, Manuel ^a,b   Luchsinger, Augusta ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b NONE   (Venezuela)

Author keywords

Arterial hypertension; Dopamine; Dopaminergic receptors

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; BROMOCRIPTINE; CARMOXIROLE; CLOZAPINE; DOMPERIDONE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; FENOLDOPAM; IBOPAMINE; LISURIDE; METOCLOPRAMIDE; NORADRENALIN; PERGOLIDE; PIRIBEDIL; QUINPIROLE; SKF 3893; SULPIRIDE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; DOPAMINE RELEASE; DRUG MECHANISM; HEART RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; STOMACH MOTILITY;

EID: 0031936052     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199801000-00007     Document Type: Review

References (52)

1. Tainter ML: The influence of cocaine and certain related compounds upon the action of sympathomimetic amines. Q J Pharmacol 1930;3:584-595.
2. Goldberg LI: A comparison of the vascular dopamine receptor with other dopamine receptors. Annu Rev Pharmacol Toxicol 1978;18:57-79.
3. Romero E, Saturno N, y Campos HA: Efectos del agotamiento de la noradrenalina y dopamina cerebrales de la rata sobre la actividad locomotriz espontánea y la estimulada por anfetamina. Acta Cient Venez 1989;40:113-118.
4. Velasco M, Tjandramaga TB, McNay JL: Differential dose-related effect of dopamine on systemic and renal hemodynamics in hypertensive patients. Clin Res 1974; 22:308A.
5. Hollenberg NK, Acams DF, Mandell P: Renal vascular response to dopamine, hemodynamics and angiographic observations in normal man. Clin Sci Mol Med 1973;45:742-773.
6. Romero E, Angeli M, Velasco M, Azar O, Bueno O, Lema G: Double-blind placebo controlled trial of terazozin effect on blood pressure and urinary output of dopamine in hypertensive patients. J Clin Pharmacol 1992;32:816-821.
7. + ATPase activity in rat proximal convoluted tubule segments. Am J Physiol 1987;252:F39-F45.
8. + exchanger. Am J Physiol 1990;258: F514-F521.
9. Muto S, Tabei K, Asano Y, Immai M: Dopamine inhibition of the action of vasopressin on the cortical collecting tubule. Eur J Pharmacol 1985;114:393-397.
10. Kebabian JW, Kalne DB: Multiple receptors of dopamine. Nature 1979;277:93-96.
11. Cavero I, Massingham R, LeFebre-Brag F: Peripheral dopamine receptors, potential for a new class of antihypertensive agents. Life Sci 1982;310:39-48.
12. Ricci A, Amenta F: Autoradiographic localization of dopamine. DA-2 receptor sites in rat mesenteric vascular tree. J Pharmacol Exp Ther 1990;254:750-755.
13. Missalle C, Costelli L, Memo M, Caruba O, Spano PF: Identification and characterization of postsynaptic D1 and D2 dopamine receptors in the cardiovascular system. J Cardiovasc Pharmacol 1988;11:643-650.
14. Malley O, Tood RD: The rat dopamine D4 receptor: sequence, gene structure and demonstration of expression in the cardiovascular system. Nature New Biol 1992;4: 137-146.
15. Ricci A, Amenta F: Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J Neuroimmunol 1994;53:1-7.
16. Luchsinger A, Velasco M, Urbina A, Morillo J, Romero E, Alvarez R, Hernández-Pieretti O: Comparative effects of dopamine agonist on cardiovascular, renal and renin angiotensin system in hypertensive patients. J Clin Pharmacol 1992;32:55-60.
17. Luchsinger A, Velasco M, Arbona E, Forte P, Sukerman M, Urbina A, Hernández O, Gómez J: Effect of domperidone on the bromocriptine induced antihypertensive action in hypertensive patients. Am J Ther 1995;2:388-394.
18. Luchsinger A, Grilli M, Forte P, Morales E, Velasco M: Metoclopramide blocks bromocriptine induced antihypertensive effects in hypertensive patients. Int J Clin Pharmacol Ther 1995;33:509-512.
19. Martín G, Forte P, Luchsinger A, Mendoza F, UrbinaQuintana A, Hernández-Pieretti O, Romero E, Velasco M: Effect of intravenous dopamine on blood pressure and plasma insulin in hypertensive patients. Eur J Clin Pharmacol 1993;45:503-505.
20. Edwards R: Comparison of the effects of fenoldopam, SK-FR87516 and dopamine on renal arterioles in vitro. Eur J Pharmacol 1986;126:167-170.
21. Frederickson Z, Bradley T, Goldberg LI: Blockade of renal effects of dopamine in the dog by DA-1 agonist SCH23390. Am J Physiol 1985;249:F236-F239.
22. Lee MR: Dopamine and the kidney. Clin Sci 1982,62:439-448.
23. Antonipillani I, Broes MI, Lang D: Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin release. Hypertension 1989,13:463-468.
24. Barret J, Wright F, Taylor R, Proakis G: Involvement of dopamine receptor subtypes in dopaminergic modulation of aldosterone secretion in rats. Life Sci 1987,40: 1499-1506.
25. Leblanc H, Lachelin GCL, Abu-Fadil, Yen SSC: The effects of dopamine infusion on insulin and glucagon secretion in man. J Clin Endocrinol Metab 1977;44:196-198.
26. Velasco M, Urbina Quintana A, Figueroa PA, Nieves D, Hernández E, Casado JG, Hernández Pieretti: Effects of indoramin and propranolol on cardiovascular responses to cold in hypertensive patients. Clin Pharmacol Ther 1982;32:7-11.
27. Gómez J, Forte P, Luchsinger A, Romero E, Arreaza R, Hernández O, Velasco M: Dopaminergic influence on the cardiovascular and hormonal responses to cold stress in hypertensive patients. Am J Ther 1995;2:175-179.
28. Velasco M, Corujo M, Valery J, Luchsinger A, Morales E: Dopaminergic influence on the cardiovascular response to exercise in normotensive and hypertensive subjects. Int J Clin Pharmacol Ther 1995;33:504-508.
29. Velasco M, Arreaza R, Luchsinger A, Gómez J, Morales E: Cardiovascular and hormonal effects of domperidone, a peripheral dopaminergic blocker, in bromocriptine treated hypertensive patients. Am J Ther 1995;2: 451-454.
30. Romero E, Velasco M, Luchsinger A: Dopamina e hipertensión arterial: implicaciones terapéuticas del uso de agonistas y antagonistas. Archives Venezolanos de Farmacología y Terapéutica 1993;12:158-163.
31. Luchsinger A, Cevallos JL: Control dopaminérgico de la secreción de prolactina en humanos. Rev Fac Med 1989;12:91-92.
32. Sued AF: Reduction in blood pressure in normal and spontaneously hypertensive rats by lergotrile mesylate. J Pharm Pharmacol 1979;31:814-817.
33. Yen T, Stamm NB, Clemens JM: Pergolide, a potent dopaminergic antihypertensive. Life Sci 1979;25:814-817.
34. Vanden BM: Differential effects of quinelorane and pergolide on behavior, blood pressure and body temperature of spontaneously hypertensive rats and WistarKyoto rats. Pharmacol Biochem Behav 1995;50:389-397.
35. Kirsten R, Breidert M, Sparwasser K, Ochs JC, Hesse K, Nelson K: Carmoxirole inhibits platelet aggregation in vitro and ex vivo. Int J Clin Pharmacol Ther 1995;2:76-80.
36. Laudron PM, Leysen JE: Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 1979;28:2161-2165.
37. Albibi R, McCallum RW: Metoclopramide: pharmacological and clinical applications. Ann Intern Med 1985; 98:86-90.
38. Mannelli M, Delitala G, Maggi M, Cuomo S, Piazzini M, Guazelli R: Effects of different dopaminergic antagonist on bromocriptine-induced inhibition of norepinephrine release. Clin Endocrinol Metab 1984;59:74-77.
39. Goldberg LI: Dopamine: receptors and clinical applications. Clin Physiol Biochem 1985;5:120-126.
40. Mocaer Z: Piribedil et systeme dopaminergique. Gaz Med Fr 1983;31:35-39.
41. White WB, Halley S: Comparative renal effects of intravenous administration of fenoldopan mesylate and sodium nitroprusside in patients with severe hypertension. Circulation 1989;149:870-874.
42. Breiz CA, Buchanan RW, Waltrip RW, Listwak S, Holmes C, Goldstein DS: The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology 1994;10:1-7.
43. Goldberg LI: Dopamine receptors and hypertension: physiologic and pharmacologic implications. Am J Med 1984;5:37-44.
44. Shigetomi S, Fukuchi S: Recent aspect of the role of peripheral dopamine and its receptors in the pathogenesis of hypertension. J Med Sci 1994;40:69-83.
45. Chatziantoniou C, Ruan X, Arendshorst WB: Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension. Proc Natl Acad Sci USA 1995;7:2924-2928.
46. Ohbu K, Kaskel FJ, Kinoshita S, Felder RA: Dopamine-1 receptors in the proximal convoluted tubule of Dah1 rats: defective coupling to adenylate-cyclase. Am J Physiol 1995;268:R231-R235.
47. Watanabe H, Ogura T, Hosaya M, Kageyama J, Ota Z: Developmental change of kidney dopamine receptors in spontaneously. Res Commun Mol Pathol Pharmacol 1995;87:333-344.
48. Andrejak M, Hary L: Enhanced dopamine renal responsiveness in patients with hypertension. Clin Pharmacol Ther 1986;40:610-614.
49. Stolba P, Husek P, Kunes J: Blood pressure changes induced by chronic insulin treatment in Wistar rats. Physiol Res 1994;6:329-334.
50. Saito I, Itsuji S, Takeshita E, Kawabe K, Nishino M, Wainai H, Hasegawa C, Saruta T, Nagano S, Sekihara T: Increased urinary dopamine excretion in young patients with essential hypertension. J Clin Hypertens 1994;1:29-39.
51. Darby JM, Yonas H, Marks, Dorham S, Sndyer RW, Memoto EM: Acute cerebral blood flow response to dopamine-induced hypertension after subarachnoid hemorrhage. J Neurosurg 1994;5:857-864.
52. Sutoo D, Akiyama K, Takita K: Hypertension in epileptic mice: a phenomenon related to reduction of Ca (2+)-dependent catecholamine synthesis in the brain. Eur J Pharmacol 1995;278:33-37.